Glujovsky Demián, Pesce Romina, Fiszbajn Gabriel, Sueldo Carlos, Hart Roger J, Ciapponi Agustín
Reproductive Medicine, CEGYR (Centro de Estudios en Ginecologia y Reproduccion), Viamonte 1438,, Buenos Aires, Argentina.
Cochrane Database Syst Rev. 2010 Jan 20(1):CD006359. doi: 10.1002/14651858.CD006359.pub2.
If a fresh embryo, assisted reproductive technology procedure cycle is unsuccessful and there are frozen embryos available, a frozen-thawed embryo transfer is performed. In some specific cases women may undergo oocyte donation treatment. In both situations the endometrium is primed by the administration of estrogen and progesterone. To prevent the possibility of spontaneous ovulation, gonadotropin-releasing hormone (GnRH) agonists are frequently used.
To evaluate the most effective endometrial preparation for women undergoing transfer with frozen embryos or embryos from donor oocytes with regard to the subsequent live birth rate.
We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, EMBASE, LILACS, and abstracts of reproductive societies' meetings (from inception). No language restrictions were applied. Experts in the field were contacted.
Randomised controlled trials evaluating endometrial preparation in women undergoing fresh donor cycles and frozen embryo transfers.
Two review authors independently applied the inclusion criteria, assessed trial risk of bias, and extracted data.
Twenty two randomised controlled trials were included. Five studies analysed the use of a GnRH agonist versus control. No significant benefit was demonstrated when using GnRH agonists. No evidence of statistically significant benefit was found for one GnRH agonist over another, or vaginal over intramuscular progesterone administration. No difference in pregnancy rate was demonstrated when no treatment was compared to aspirin, steroids, ovarian stimulation, or human chorionic gonadotropin (hCG) prior to embryo transfer, although using hCG several times before the oocyte retrieval decreases the pregnancy rate. Finally, when oocyte recipients were studied further, starting progesterone on the day of oocyte pick-up (OPU) or the day after OPU produced a significantly higher pregnancy rate (OR 1.87, 95% CI 1.13 to 3.08) than when recipients started progesterone the day prior to OPU.
AUTHORS' CONCLUSIONS: There is insufficient evidence to recommend any one particular protocol for endometrial preparation over another with regard to pregnancy rates after embryo transfers. These were either frozen embryos or embryos derived from donor oocytes. However, there is evidence of a lower pregnancy rate and a higher cycle cancellation rate when the progesterone supplementation is commenced prior to oocyte retrieval in oocyte donation cycles. Adequately powered studies are needed to evaluate each treatment more accurately.
如果新鲜胚胎辅助生殖技术周期未成功且有冷冻胚胎可用,则进行冻融胚胎移植。在某些特定情况下,女性可能会接受卵母细胞捐赠治疗。在这两种情况下,子宫内膜都通过给予雌激素和孕激素来进行预处理。为防止自发排卵的可能性,常使用促性腺激素释放激素(GnRH)激动剂。
就后续活产率而言,评估接受冷冻胚胎或供体卵母细胞来源胚胎移植的女性最有效的子宫内膜预处理方法。
我们检索了Cochrane月经紊乱与生育力低下小组试验注册库、Cochrane对照试验中央注册库(CENTRAL)(Cochrane图书馆)、MEDLINE、EMBASE、LILACS以及生殖学会会议摘要(自起始)。未设语言限制。联系了该领域的专家。
评估新鲜供体周期和冷冻胚胎移植女性子宫内膜预处理的随机对照试验。
两位综述作者独立应用纳入标准、评估试验偏倚风险并提取数据。
纳入了22项随机对照试验。五项研究分析了GnRH激动剂与对照的使用情况。使用GnRH激动剂未显示出显著益处。未发现一种GnRH激动剂比另一种有统计学显著益处的证据,也未发现阴道给予孕激素与肌肉注射孕激素相比有显著益处的证据。在胚胎移植前,未治疗与阿司匹林、类固醇、卵巢刺激或人绒毛膜促性腺激素(hCG)相比,妊娠率无差异,尽管在取卵前多次使用hCG会降低妊娠率。最后,在对卵母细胞接受者进行进一步研究时,在取卵日(OPU)或取卵后一天开始使用孕激素的妊娠率(OR 1.87,95%CI 1.13至3.08)显著高于在取卵前一天开始使用孕激素的接受者。
就胚胎移植后的妊娠率而言,没有足够的证据推荐任何一种特定的子宫内膜预处理方案优于另一种。这些胚胎要么是冷冻胚胎,要么是供体卵母细胞来源的胚胎。然而,有证据表明在卵母细胞捐赠周期中,在取卵前开始补充孕激素时妊娠率较低且周期取消率较高。需要进行有足够样本量的研究以更准确地评估每种治疗方法。